Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROCO:4186'
s EV-to-FCF Range Over the Past 10 Years
Min: -72.07 Med: -10.65 Max: 2844.82
Current: 52.42
During the past 13 years, the highest EV-to-FCF of Taiwan Advance Bio-Pharmaceutical was 2844.82. The lowest was -72.07. And the median was -10.65.
ROCO:4186's EV-to-FCF is ranked worse than 78.74% of 334
companies
in the Biotechnology industry
Industry Median: 15.69
vs ROCO:4186: 52.42
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Taiwan Advance Bio-Pharmaceutical's PE Ratio (TTM) for today is calculated as:
Taiwan Advance Bio-Pharmaceutical's share price for today is NT$10.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Taiwan Advance Bio-Pharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.310.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Taiwan Advance Bio-Pharmaceutical EV-to-FCF Related Terms
Taiwan Advance Bio-Pharmaceutical EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4186 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Taiwan Advance Bio-Pharmaceutical's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiwan Advance Bio-Pharmaceutical EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Taiwan Advance Bio-Pharmaceutical's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Taiwan Advance Bio-Pharmaceutical's EV-to-FCF falls into.
Taiwan Advance Bio-Pharmaceutical's current Enterprise Value is NT$1,032.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Taiwan Advance Bio-Pharmaceutical's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$19.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiwan Advance Bio-Pharmaceutical (ROCO:4186) has a EV-to-FCF of 52.20 as of Jul. 16, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Taiwan Advance Bio-Pharmaceutical and its competitors. According to the industry distribution chart, Taiwan Advance Bio-Pharmaceutical ranks #263 out of 334 companies in the Biotechnology industry, placing it in the top 78.7%.
Is Taiwan Advance Bio-Pharmaceutical's EV-to-FCF too high?
Taiwan Advance Bio-Pharmaceutical's current EV-to-FCF is 52.20. The Biotechnology industry median EV-to-FCF is 15.69. Taiwan Advance Bio-Pharmaceutical's value of 52.20 is 232.7% above this industry median. Based on the distribution chart, Taiwan Advance Bio-Pharmaceutical ranks #263 out of 334 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Taiwan Advance Bio-Pharmaceutical has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Taiwan Advance Bio-Pharmaceutical's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Taiwan Advance Bio-Pharmaceutical ranks #263 out of 334 companies for EV-to-FCF. This places Taiwan Advance Bio-Pharmaceutical in the lower half of its industry. The industry median EV-to-FCF is 15.69. Taiwan Advance Bio-Pharmaceutical's value of 52.20 is 232.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.69, based on 334 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Taiwan Advance Bio-Pharmaceutical's current EV-to-FCF of 52.20 is 232.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Taiwan Advance Bio-Pharmaceutical and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiwan Advance Bio-Pharmaceutical's current EV-to-FCF is 52.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Advance Bio-Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Advance Bio-Pharmaceutical (ROCO:4186) is currently considered Possible Value Trap. The stock's GF Value™ is NT$17.91, compared to a current price of NT$10.00 — trading 44.2% below its estimated fair value. The current EV-to-FCF is 52.20 and 232.7% above the Biotechnology industry median of 15.69. Taiwan Advance Bio-Pharmaceutical's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Taiwan Advance Bio-Pharmaceutical (ROCO:4186), the current EV-to-FCF is 52.20 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiwan Advance Bio-Pharmaceutical (ROCO:4186) Overvalued in 2026?
Based on GuruFocus' analysis, Taiwan Advance Bio-Pharmaceutical stock appears to be undervalued.
The current stock price of NT$10.00 is trading 44.2% below its estimated GF Value™ of NT$17.91.
GuruFocus considers Taiwan Advance Bio-Pharmaceutical to be Possible Value Trap.
Key valuation signals for ROCO:4186:
EV-to-FCF: 52.20
GF Value™: NT$17.91 vs. price of NT$10.00 (44.2% below fair value)
Industry Position: 232.7% above the Biotechnology median (#263 of 334)
No single metric tells the full story. See the ROCO:4186 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiwan Advance Bio-Pharmaceutical Business Description
Taiwan Advance Bio-Pharmaceutical Inc operates in the food safety industry. The company's products include a Food safety test kit, Animal test kit, Pesticide test kit, Mycotoxin test kit, Nuleic acid extraction kit.
52GF Score
Get the complete analysis for ROCO:4186
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4186 has been successfully added to your 
